$41.21
0.61% yesterday
Nasdaq, Dec 31, 10:00 pm CET
ISIN
US2528281080
Symbol
DNTH

Dianthus Therapeutics Stock price

$41.21
-1.99 4.61% 1M
+22.58 121.20% 6M
+19.41 89.04% YTD
+19.41 89.04% 1Y
+34.89 552.06% 3Y
-84.23 67.15% 5Y
-191.11 82.26% 10Y
-191.11 82.26% 20Y
Nasdaq, Closing price Wed, Dec 31 2025
+0.25 0.61%
ISIN
US2528281080
Symbol
DNTH
Industry

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.4b
Net debt
positive
Cash
$402.6m
Shares outstanding
42.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
570.2 | 807.4
EV/Sales
439.5 | 622.3
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
94.2%
Return on Equity
-24.1%
ROCE
-25.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.1m | $2.2m
EBITDA
$-140.2m | -
EBIT
$-140.3m | $-161.9m
Net Income
$-126.4m | $-159.3m
Free Cash Flow
$-109.6m
Growth (TTM | estimate)
Revenue
-42.6% | -65.1%
EBITDA
-69.8% | -
EBIT
-69.2% | -58.9%
Net Income
-88.3% | -87.4%
Free Cash Flow
-74.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,553.2% | -
EBIT
-4,558.4%
Net
-4,104.8% | -7,321.8%
Free Cash Flow
-3,561.6%
More
EPS
$-3.3
FCF per Share
$-2.6
Short interest
11.3%
Employees
78
Rev per Employee
$80.0k
Show more

Is Dianthus Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Dianthus Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Dianthus Therapeutics forecast:

20x Buy
95%
1x Hold
5%

Analyst Opinions

21 Analysts have issued a Dianthus Therapeutics forecast:

Buy
95%
Hold
5%

Financial data from Dianthus Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3.08 3.08
43% 43%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
37% 37%
1,015%
- Research and Development Expense 112 112
71% 71%
3,640%
-140 -140
70% 70%
-4,550%
- Depreciation and Amortization 0.16 0.16
54% 54%
5%
EBIT (Operating Income) EBIT -140 -140
69% 69%
-4,555%
Net Profit -126 -126
88% 88%
-4,102%

In millions USD.

Don't miss a Thing! We will send you all news about Dianthus Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Head office United States
Employees 78
Website dianthustx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today